The results of stability studies and Kac binding experiments suggest that cancer-associated PBRM1-BD4 missense variants impacting residues in either the Kac binding loops or the structural core are sufficient to decrease PBRM1-BD4 Kac by disrupting key bromodomain functional regions. This evidence concerns the gene PBRM1 and cancer.